Innovative MulticOmponent Drug dEsign (IMODE) for enhancing regional strategic advantages in pharmaceutical and biomedical applications (Q4295784): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item: Edited by the materialized bot - inferring region from the coordinates)
(‎Changed an Item: Attach the beneficiary based on the string)
Property / beneficiary
 
Property / beneficiary: Q4358357 / rank
 
Normal rank

Revision as of 10:39, 22 June 2022

Project Q4295784 in France, United Kingdom, Belgium
Language Label Description Also known as
English
Innovative MulticOmponent Drug dEsign (IMODE) for enhancing regional strategic advantages in pharmaceutical and biomedical applications
Project Q4295784 in France, United Kingdom, Belgium

    Statements

    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    3,576,035.7 Euro
    0 references
    5,960,059.5 Euro
    0 references
    60.0 percent
    0 references
    1 July 2016
    0 references
    30 June 2021
    0 references
    Université de Lille|Université Lille1
    0 references
    0 references

    51°2'9.60"N, 3°43'38.28"E
    0 references

    51°23'50.14"N, 0°32'18.10"E
    0 references

    52°37'45.70"N, 1°15'26.96"E
    0 references

    50°36'18.22"N, 3°2'24.90"E
    0 references

    51°21'21.64"N, 0°32'9.42"W
    0 references

    51°31'29.46"N, 0°7'26.18"W
    0 references

    50°36'41.08"N, 3°8'26.16"E
    0 references

    50°36'19.37"N, 3°1'42.78"E
    0 references

    51°23'30.80"N, 0°31'4.76"E
    0 references

    50°36'12.64"N, 3°2'14.75"E
    0 references

    50°37'57.11"N, 2°40'48.18"E
    0 references
    The overall objective is to enhance R&D on major societal challenges for improved healthcare by developing solutions for novel pharmaceutical products and medical devices through new multicomponent drug systems. Our strategy will involve major stakeholders in the field including Universities, small and large entreprises and final users (patients) as well as an economic development agency. Technology transfer and industrial competitiveness will be enhanced. Trainings through technological develop. will create highly skilled scientists reducing the shortage of qualified staff in the field. (English)
    0 references

    Identifiers

    0 references